# A Study of SYS6051 in Subjects With Advanced Solid Tumors

> **NCT07591285** · PHASE1 · NOT_YET_RECRUITING · sponsor: **CSPC Megalith Biopharmaceutical Co.,Ltd.** · enrollment: 114 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** SYS6051

## Key facts

- **NCT ID:** NCT07591285
- **Lead sponsor:** CSPC Megalith Biopharmaceutical Co.,Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-12
- **Primary completion:** 2028-05-31
- **Final completion:** 2028-06-30
- **Target enrollment:** 114 (ESTIMATED)
- **Last updated:** 2026-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07591285

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07591285, "A Study of SYS6051 in Subjects With Advanced Solid Tumors". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT07591285. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*